Work

Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics

Year: 2019
Type: review
Abstract: Peptides and small protein scaffolds are gaining increasing interest as therapeutics. Similarly to full-length antibodies, they can bind a target with a high binding affinity and specificity while remaining small enough to diffuse into tissues. However, despite their numerous advantages, small biotherapeutics often suffer from a relatively short circulating half-life, thus requiring frequent applications that ultimately restrict their ease of use and user compliance. To overcome this limitation, a large variety of half-life extension strategies have been developed in the last decades. Linkage to ligands that non-covalently bind to albumin, the most abundant serum protein with a circulating half-life of ∼19 days in humans, represents one of the most successful approaches for the generation of long-lasting biotherapeutics with improved pharmacokinetic properties and superior efficacy in the clinic.
Source: MedChemComm
Language: English
Open Access status: green
OpenAlex ID: W2948205513
FWCI: 1.649
Cites: 104
Cited by: 188
Related to: 10